WebFeb 8, 2016 · The registry’s national clinical trial number must be recorded on the claim. Consistent with section 1142 of the Social Security Act (the Act), the Agency for Healthcare Research and Quality (AHRQ) supports clinical research studies that CMS determines address the above-listed research questions and the a-m criteria listed in Section c. of ... Web• Clinical Trial Number(s): Mandatory reporting of the applicable 8-digit clinical trial or registry number for study or registry participation since TAVR is covered only under CED. • The 8-digit numeric clinical trial number should be placed in the value amount of value code D4 on the paper claim UB-40 (Form Locators 39-41) or in Loop 2300 ...
WATCHMAN FLX™ Currently Enrolling Trials & Clinical Trial Results
WebNov 2, 2024 · Pooled meta-analysis of PREVAIL and PROTECT-AF trials at 5 years: Cardiovascular death, stroke, or systemic embolism occurred in 2.8% of the device … WebSep 17, 2024 · Total number of enrollees: 1,878 Duration of follow-up: 18 months Mean patient age: 75 years Percentage female: 41% Inclusion criteria: Nonvalvular AF (paroxysmal, persistent, or permanent) CHA 2 DS 2 -VASc score of ≥3 Suitable for short-term OAC, but not suitable for long-term OAC Exclusion criteria: haverhill pharmacy
Code Z00.6 and Clinical Trials - hiacode.com
WebNov 27, 2024 · The Watchman Left Atrial Appendage System (Boston Scientific) is a self-expanding nickel titanium device. It has a polyester covering and fixation barbs for attachment to the endocardium. Implantation is performed percutaneously through a catheter delivery system, using venous access and transseptal puncture to enter the left … WebThe SURPASS analysis of the NCDR-LAAO Registry™ includes the largest number of commercial WATCHMAN FLX patients to date. This data reinforces the outstanding safety of WATCHMAN FLX with 0.37% major procedural adverse event rate within 7 days or hospital discharge and 98% procedural success rate in > 16,000 real-world NVAF … WebMar 16, 2024 · SURPASS includes 16,048 patients from the NCDR-LAAO Registry who received Watchman FLX and had data available at discharge; of these, 14,107 had data at 45 days after implantation. The overall cohort had the following characteristics: Mean age, 76 years 40% female Mean CHA 2 DS 2 -VASc score, 4.8 Mean HAS-BLED score, 2.4 haverhill permit